s
Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD)
22-01-2024, 12:49
LACHEN, Switzerland, Jan. 22, 2024 /PRNewswire/ — Octapharma announced today the publication of the results from the clinical study WIL-31, which investigated the efficacy and safety of prophylaxis with wilate®, a von Willebrand factor/factor VIII (VWF/FVIII) concentrate, in patients with all types of von Willebrand disease (VWD). The results have been published in the leading […] L'articolo Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD) proviene da La Ragione.
CONTINUA A LEGGERE
16
0
0
Guarda anche
Libero Quotidiano
![Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024](/img/static/get.php?image=https://www.liberoquotidiano.it/assets/images/placeholder_libero_gallery.png)
Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024
La Ragione
22:12
Le Pen: “La marea cresce, la nostra vittoria è solo rimandata”
La Ragione
19:43
Keys si fa male e si ritira, Paolini ai quarti di Wimbledon
La Ragione
19:34
Domina, poi soffre, ma vince in tre set: Sinner ai quarti
La Ragione
19:06